H.C. Wainwright lowered the firm’s price target on Enanta (ENTA) to $18 from $27 and keeps a Buy rating on the shares. Zelicapavir successfully met the virology endpoint of RSVPEDs, a Phase 2 placebo-controlled study of zelicapavir focused on pediatric patients aged 28 days to 36 months with RSV in both hospitalized and nonhospitalized settings, but the firm has “several concerns” on zelicapavir’s ability in RSV symptom reduction, the analyst tells investors. Following the report of the top-line dataset from the trial, the firm is reducing its assumed probability of success for zelicapavir in RSV to 50% from 60%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
- Enanta price target lowered to $20 from $30 at Evercore ISI
- Enanta Pharmaceuticals Reports Promising Results for Pediatric RSV Drug
- Enanta announces ‘positive’ results from Phase 2 study of zelicapavir
- Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility
- Enanta price target lowered to $14 from $16 at Oppenheimer